

HER2-targeted Therapy for Metastatic Breast Cancer

A Multidisciplinary Approach

Friday 28 September 2012 | 16:30–18:30

Hall N-O, Austria Center Vienna, Austria

37th ESMO Congress



Faculty

Professor Michael Gnant, *Austria (Co-Chair)*

Dr Hope S. Rugo, *USA (Co-Chair)*

Dr Thomas Bachelot, *France*

Professor David Cameron, *UK*

Gill Donovan, *RGN, UK*

Professor Rob Horne, *UK*

Visit the GSK booth (Hall Y, Booth Y100) for more information and to request symposium highlights

Programme

16:30–16:40 **Welcome and introductions**

16:40–17:00 **Targeting the HER2 receptor: Current and emerging therapeutic strategies**

17:00–18:15 **Decision-making in the clinic: Interactive case studies with a multidisciplinary panel discussion**

Case 1: Treatment options following progression on trastuzumab

Case 2: Management of brain metastases in HER2-positive breast cancer

18:15–18:25 **Closing remarks**

[Click here to access prescribing information for Tyverb[®] ▼ \(lapatinib\)](#)

GlaxoSmithKline funded this symposium, selected the speakers, and provided input into the agenda and content

